Navigation Links
Angiotech Pharmaceuticals, Inc. announces filing of shelf-registration statement
Date:7/23/2009

VANCOUVER, July 23 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today filed a preliminary short form base shelf prospectus with the securities commissions of British Columbia and Ontario and a corresponding shelf registration statement on Form S-3 with the United States Securities and Exchange Commission (collectively, the "Offering Documents"). The Offering Documents, when made final and / or declared effective, will allow Angiotech to make offerings of Common shares, Class I Preference shares, debt securities, warrants or units for initial aggregate proceeds of up to US$250 million during the next 25 months to potential purchasers in British Columbia, Ontario and the United States. Angiotech intends to use the proceeds from any such offering for general corporate purposes, including funding research and development programs, capital expenditures, working capital and/or repayment or refinancing of the Company's outstanding indebtedness, except as otherwise indicated in the applicable prospectus supplement related to any such offering.

A registration statement relating to these securities has been filed with the United States Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

    Forward Looking Statements
    --------------------------

Statements contained in this press release that are not based on historical
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... July 31, 2015 In today,s fast ... help them drive positive health outcomes, improve profitability ... of patient care in their communities. At ThoughtSpot ... and conference, AmerisourceBergen announced a new set of ... Administration Organization and help independent pharmacies endure the ...
(Date:7/30/2015)... ... July 31, 2015 , ... Ralco is honored to announce that ... County Fair to be held August 5-9 in Marshall. The Ralco Enrichment Center is ... from and how agriculture impacts their daily lives. This unique exhibit also features a ...
(Date:7/30/2015)... ... 30, 2015 , ... The 2015 Market Research Report on the Global ... the global Propanol market with a focus on the Chinese situation. Major companies included ... Oxea, ISU Chemical, Sanofi, Royal Dutch Shell, LG Chem and Zhejiang Xinhua Chemical. , ...
(Date:7/30/2015)... 30, 2015   Senomyx , Inc. (NASDAQ: ... technologies to discover, develop, and commercialize novel flavor ingredients ... reported financial results for the second quarter 2015. ... we remain on track to achieve our commercial and ... Officer of the Company. "Since our last quarterly earnings ...
Breaking Biology Technology:AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 3Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9
... Recent action in Congress to reauthorize the U.S. ... address the social and ethical issues concerning the ... to address social and ethical issues now as ... nanotechnology and its possible significant contributions to our ...
... N.J., Jan. 27 Alfacell Corporation (OTC Bulletin Board: ... meeting with the U.S. Food and Drug Administration (FDA) ... components of the ONCONASE rolling New Drug Application (NDA) ... At the pre-NDA meeting, the FDA provided guidance ...
... Efficacy and Excellent TolerabilityCORONA, Calif., Jan. 27 Watson ... in generic and specialty branded pharmaceuticals, announced today that ... GELNIQUE(TM) (oxybutynin chloride) Gel 10%, the first and only ... with symptoms of urge urinary incontinence, urgency, and frequency. ...
Cached Biology Technology:Ethical evaluations of nanotechnology 2Alfacell Provides ONCONASE(R) NDA Submission Update 2Alfacell Provides ONCONASE(R) NDA Submission Update 3Watson's GELNIQUE(TM) (oxybutynin chloride) Gel 10% Approved by FDA for the Treatment of Overactive Bladder 2Watson's GELNIQUE(TM) (oxybutynin chloride) Gel 10% Approved by FDA for the Treatment of Overactive Bladder 3Watson's GELNIQUE(TM) (oxybutynin chloride) Gel 10% Approved by FDA for the Treatment of Overactive Bladder 4
(Date:7/9/2015)... SAN JOSE, Calif. , July 9, 2015 /PRNewswire/ ... human interface solutions, announced today that it will report ... 2015 on Thursday, July 30, 2015 after the close ... call for analysts and investors at 2:00 p.m. PT ... information.    To participate on the live ...
(Date:7/9/2015)... 2015  Unchained Labs just can,t get enough ... Avid Nano. Avid Nano designs, develops and manufactures ... Also today, Unchained Labs UNcaged the ... use protein sizing system. The pUNk is a ... size, size distribution, aggregation population and molecular weight. ...
(Date:7/8/2015)... , July 8, 2015 Summary ... and the fourth most fatal, with a mortality rate ... poor prognosis of pancreatic cancer patients has highlighted a ... which is not being met by the current market. ... array of products with varying molecule types and mechanisms ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3
... 2008 Elsevier is pleased to announce that eight ... the annual BMA Medical Book Competition ceremony in London ... were highly commended and five received commendation. In total, ... 130 prizes awarded with 23 first prizes, 63 highly ...
... tie a mother to her newborn may be stronger in ... cesarean section, according to a study published by Yale School ... of Child Psychology and Psychiatry . The researchers, ... M.D., recruited two groups of parents from postpartum wards. One ...
... University of Cincinnati (UC) researchers have received a grant in ... of Aerospace Medicine to determine the ideal time to fly ... rush to move them from the battlefield into a safe ... getting these wounded soldiers to a cleaner, safer environment," explains ...
Cached Biology News:Elsevier congratulates its British Medical Association Award winning medical authors and editors 2Natural childbirth linked to stronger baby bonding than C-sections 2US Air Force grant targets medical evacuation procedures 2US Air Force grant targets medical evacuation procedures 3US Air Force grant targets medical evacuation procedures 4
Request Info...
Amyloid stain....
Dopamine D2 and D3 receptor, human and possibly mouse. AB1502 detects 40 ng of dopamine receptor peptide by ELISA. AB1502 is not neutralizing....
Rabbit polyclonal to Factor IX ( Abpromise for all tested applications). entrezGeneID: 2158 SwissProtID: P00740...
Biology Products: